Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lipopolysaccharide-induced necroptosis of brain microvascular endothelial cells can be prevented by inhibition of endothelin receptors

Y. Abdul, R. Ward, G. Dong, A. Ergul

. 2018 ; 67 (Suppl. 1) : S227-S236.
. 2018 ; () : S227-S236.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19005324

Over activation of the endothelin-1 (ET-1) system in disease states contributes to endothelial dysfunction. On the other hand, ET-1 promotes proliferation and survival of endothelial cells. Regulation of programmed cell death (PCD) pathways is critical for cell survival. Recently discovered necroptosis (regulated necrosis) is a pathological PCD mechanism mediated by the activation of toll like receptor 4 (TLR4), which also happens to stimulate ET-1 production in dendritic cells. To establish the effect of ET-1 on PCD and survival of human brain microvascular endothelial cells (BMVECs) under control and inflammatory conditions, BMVECs were treated with ET-1 (10 nM, 100 nM and 1 microM) or lipopolysaccharide (LPS, 100 ng/ml). ET receptors were blocked with bosentan (10 microM). Under normal growth conditions, exogenous ET-1 reduced BMVEC viability and migration at a relatively high concentration (1 microM). This was accompanied with activation of necroptosis and apoptosis marker genes. LPS decreased endogenous ET-1 secretion, increased ET(B) receptor expression and activated necroptosis. Even though ET-1 levels were low (less than 10 nM levels used under normal growth conditions), blocking of ET receptors with bosentan inhibited the necroptosis pathway and improved the cell migration ability of BMVECs, suggesting that under inflammatory conditions, ET-1 activates PCD pathways in BMVECs even at physiological levels.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19005324
003      
CZ-PrNML
005      
20210531151456.0
007      
ta
008      
190204s2018 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.933842 $2 doi
035    __
$a (PubMed)29947542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Abdul, Y. $u Department of Physiology, Augusta University, Augusta, GA, USA
245    10
$a Lipopolysaccharide-induced necroptosis of brain microvascular endothelial cells can be prevented by inhibition of endothelin receptors / $c Y. Abdul, R. Ward, G. Dong, A. Ergul
520    9_
$a Over activation of the endothelin-1 (ET-1) system in disease states contributes to endothelial dysfunction. On the other hand, ET-1 promotes proliferation and survival of endothelial cells. Regulation of programmed cell death (PCD) pathways is critical for cell survival. Recently discovered necroptosis (regulated necrosis) is a pathological PCD mechanism mediated by the activation of toll like receptor 4 (TLR4), which also happens to stimulate ET-1 production in dendritic cells. To establish the effect of ET-1 on PCD and survival of human brain microvascular endothelial cells (BMVECs) under control and inflammatory conditions, BMVECs were treated with ET-1 (10 nM, 100 nM and 1 microM) or lipopolysaccharide (LPS, 100 ng/ml). ET receptors were blocked with bosentan (10 microM). Under normal growth conditions, exogenous ET-1 reduced BMVEC viability and migration at a relatively high concentration (1 microM). This was accompanied with activation of necroptosis and apoptosis marker genes. LPS decreased endogenous ET-1 secretion, increased ET(B) receptor expression and activated necroptosis. Even though ET-1 levels were low (less than 10 nM levels used under normal growth conditions), blocking of ET receptors with bosentan inhibited the necroptosis pathway and improved the cell migration ability of BMVECs, suggesting that under inflammatory conditions, ET-1 activates PCD pathways in BMVECs even at physiological levels.
650    _2
$a apoptóza $x účinky léků $x fyziologie $7 D017209
650    _2
$a mozek $x účinky léků $x metabolismus $7 D001921
650    _2
$a transformované buněčné linie $7 D002461
650    _2
$a viabilita buněk $x účinky léků $x fyziologie $7 D002470
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a endoteliální buňky $x účinky léků $x metabolismus $7 D042783
650    _2
$a antagonisté endotelinového receptoru $x farmakologie $7 D065128
650    _2
$a lidé $7 D006801
650    _2
$a lipopolysacharidy $x toxicita $7 D008070
650    _2
$a mikrocévy $x účinky léků $x metabolismus $7 D055806
650    _2
$a nekróza $x chemicky indukované $x metabolismus $7 D009336
650    _2
$a receptory endotelinů $x metabolismus $7 D017466
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ward, R. $u Department of Neuroscience and Regenerative Medicine, Augusta University, Augusta, GA, USA
700    1_
$a Dong, G. $u Department of Physiology, Augusta University, Augusta, GA, USA
700    1_
$a Ergul, A. $u Department of Physiology, Augusta University, Augusta, GA, USA; Charlie Norwood Veterans Affairs Medical Center, Augusta, GA, USA
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 67, Suppl. 1 (2018), s. S227-S236
773    0_
$t ET-15 $g (2018), s. S227-S236 $w MED00206979
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29947542 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20190204 $b ABA008
991    __
$a 20210531151455 $b ABA008
999    __
$a ok $b bmc $g 1376287 $s 1043529
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 67 $c Suppl. 1 $d S227-S236 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
BMC    __
$a 2018 $d S227-S236 $m ET-15 $x MED00206979
LZP    __
$b NLK118 $a Pubmed-20190204

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...